There are multiple ongoing or completed randomized phase II and phase III studies of PD-1/PD-L1 antibodies combined with VEGF inhibitors [23], including hepatocellular cancer [24], renal cell carcinoma [25], and lung cancer [26]. Here, VEGFA is linked to lung carcinoma.